Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expands By 86.3%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 742,800 shares, a growth of 86.3% from the February 13th total of 398,700 shares. Based on an average trading volume of 817,700 shares, the short-interest ratio is currently 0.9 days. Currently, 1.5% of the company’s stock are short sold.

Institutional Trading of Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jones Financial Companies Lllp raised its stake in Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after buying an additional 10,000 shares during the period. National Bank of Canada FI increased its stake in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after purchasing an additional 11,600 shares during the period. Atria Investments Inc increased its stake in shares of Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after purchasing an additional 12,430 shares during the period. PVG Asset Management Corp bought a new position in shares of Milestone Pharmaceuticals during the third quarter worth approximately $46,000. Finally, Northern Trust Corp increased its stake in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after purchasing an additional 30,772 shares during the period. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Up 6.9 %

MIST traded up $0.14 on Friday, hitting $2.17. 2,438,222 shares of the company were exchanged, compared to its average volume of 388,516. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The stock’s fifty day moving average is $2.02 and its 200-day moving average is $1.79. The company has a market cap of $115.72 million, a PE ratio of -2.68 and a beta of 1.83. Milestone Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $2.75.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Friday, February 28th.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.